Ventricular Premature Complexes
Conditions
Interventions
Sponsors
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) ? Meet the diagnostic standard of Western medicine for ventricular premature complexes ? The ventricular premature frequency stratification is Myerburg grade 3-4 and the morphological stratification is A-D grade, ?Patients with ventricular premature complexes with 500 times/24h=premature beats=10000 times/24h . (2) TCM syndrome differentiation is a patient with ventricular premature contraction of deficiency of both Yin and Yang. (3) The age is between 18 to 75 years old. (4) Did not participate in other drug clinical trials before being selected; (5) Volunteer to participate in this clinical study and sign the informed consent form, insist on taking the medication for 4 weeks, and complete the pre- and post-treatment scales, blood test and examination, and have fixed contact information to be able to complete the follow-up work.
Exclusion criteria
Exclusion criteria: (1)Suffer from bradyarrhythmia (<50 times/min) including sick sinus syndrome and atrioventricular block (second or third-degree atrioventricular block) (2) Persistent ventricular tachycardia, non-sustained ventricular tachycardia and persistent atrial fibrillation (3) Those who are seriously ill and need to be treated with other anti-arrhythmic drugs or are accompanied by other serious diseases (4) Arrhythmia caused by drugs, electrolyte disturbances, acid-base balance disorders, emotions and other factors; (5) Patients with unstable angina pectoris, myocardial infarction and various cardiomyopathy of coronary heart disease; uncontrolled hypertension, such as grade 3 hypertension or higher risk or higher, or severe hypotension; uncontrolled diabetes patients; liver In renal function tests, alanine aminotransferase or aspartate aminotransferase exceeds the upper limit of the normal reference value by 1.5 times, the urea nitrogen exceeds the upper limit of the normal reference value by 1.2 times, and the blood creatinine exceeds the upper limit of the normal reference value; severe respiratory dysfunction or Asthma; primary hematopoietic system diseases, other system diseases (such as hyperthyroidism, etc.), poor peripheral circulation, severe peripheral vascular disease, and premature ventricular contractions caused by unknown etiology; (6) People with allergies, mental patients, heavy drinking, and smokers; (7) Women in pregnancy or lactating period; (8) Those who are taking ß-blockers or have contraindications to ß-blockers; (9) Those who have participated in other clinical trials in the past 3 months or who are deemed unsuitable by researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| QT dispersion;Number of premature ventricular beats;Tpeak-end dispersion;Tpeak-end interval; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total heart rate;Patient Health Questionnaire-9 (PHQ-9);Maximum heart rate;Hepatic function test;Blood routine;Generalized Anxiety Disorder-7 (GAD-7);Self-Rating Anxiety Scale(SAS);Average heart rate;Minimum heart rate;Renal function test;Self-Rating Depression Scale (SDS);TCM Symptom Scale; | — |
Countries
China
Contacts
Public ContactHe Qing Yong
Outcome results
None listed